What is Retatrutide?
Retatrutide is a once-weekly peptide agonist targeting GIP, GLP-1 and glucagon receptors. It is being developed by Eli Lilly for obesity and related metabolic conditions.
Proposed mechanism
Retatrutide combines incretin signalling through GIP and GLP-1 receptors with glucagon-receptor activity. The goal is to influence appetite, glucose regulation and energy expenditure through three coordinated hormonal pathways.
What has been published?
The 2023 Phase II obesity trial showed substantial dose-dependent weight loss. In 2026 Lilly reported positive Phase III results from TRIUMPH studies, including large average weight reductions in obesity trials.
Current human evidence
Retatrutide now has a much stronger human evidence base than research-market peptides. Even so, pivotal trial results and an investigational status are not the same as regulatory approval, and safety/benefit conclusions continue to depend on full trial evaluation.
Regulatory status
As of August 2026, retatrutide remains investigational. Lilly has stated that it plans a US regulatory submission in 2027.
Possible areas of research interest
- Obesity treatment
- Type 2 diabetes
- Triple-agonist pharmacology
- Cardiometabolic outcomes
Important limitations
- Not yet an approved medicine
- Some Phase III data are currently topline company-reported results
- Long-term post-approval safety data do not yet exist
- Research-market products claiming to be retatrutide are not equivalent to trial medicine
References
AEVLI prioritizes primary publications and regulator materials over anecdotal claims.